Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
US Army
QuintilesIMS
Chinese Patent Office
Novartis
Cerilliant
Dow
Express Scripts
McKinsey
Fuji

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,889,115

« Back to Dashboard

Summary for Patent: 8,889,115
Title:Ion binding polymers and uses thereof
Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Inventor(s): Charmot; Dominique (Campbell, CA), Chang; Han-Ting (Livermore, CA), Klaerner; Gerrit (Los Gatos, CA), Buysse; Jerry M. (Los Altos, CA), Liu; Mingjun (Campbell, CA)
Assignee: Relypsa, Inc. (Redwood City, CA)
Application Number:13/647,894
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,889,115

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF HYPERKALEMIA ➤ Subscribe
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-002 Oct 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF HYPERKALEMIA ➤ Subscribe
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF HYPERKALEMIA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,889,115

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,409,561 Methods and compositions for treatment of ion imbalances ➤ Subscribe
8,282,960 Ion binding compositions ➤ Subscribe
7,429,394 Ion binding compositions ➤ Subscribe
8,778,324 Ion binding polymers and uses thereof ➤ Subscribe
8,192,758 Ion binding compositions ➤ Subscribe
7,854,924 Methods and compositions for treatment of ion imbalances ➤ Subscribe
8,282,913 Ion binding polymers and uses thereof ➤ Subscribe
8,445,014 Ion binding compositions ➤ Subscribe
8,147,873 Methods and compositions for treatment of ion imbalances ➤ Subscribe
7,488,495 Ion binding polymers and uses thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,889,115

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 2269589 ➤ Subscribe
Portugal 2184059 ➤ Subscribe
Mexico PA06011270 ➤ Subscribe
South Korea 20130086262 ➤ Subscribe
South Korea 101399238 ➤ Subscribe
South Korea 20140003661 ➤ Subscribe
South Korea 101362509 ➤ Subscribe
South Korea 20120130255 ➤ Subscribe
South Korea 101269766 ➤ Subscribe
South Korea 20120060920 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Julphar
Argus Health
US Department of Justice
Covington
Cantor Fitzgerald
AstraZeneca
Fish and Richardson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot